Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Jun;15(6):585-593.
doi: 10.1002/alr.23531. Epub 2025 Jan 15.

Unilateral Versus Bilateral Endoscopic Resection of Olfactory Neuroblastoma: Pooled Analysis From Prospective and Retrospective Multicenter Data

Arash Abiri  1 , Theodore V Nguyen  1 , Haidee Chen  2 , Elise Krippaehne  3 , David K Lerner  4 , Arifeen S Rahman  5 , Pooya Roozdar  5 , Brandon R Rosvall  6 , Michael Sabbaj  3 , Alan D Workman  4 , Shannon Wu  5 , Nithin D Adappa  4 , Daniel M Beswick  2 , Eugene H Chang  7 , Michael T Chang  5 , Garret Choby  6 , Jacob G Eide  8 , Jennifer E Douglas  4 , Mathew Geltzeiler  3 , Michael A Kohanski  4 , Peter H Hwang  5 , Christopher H Le  7 , Jivianne T Lee  2 , Jayakar V Nayak  5 , James N Palmer  4 , Zara M Patel  5 , Carlos D Pinheiro-Neto  8 , Adam C Resnick  4 , Timothy L Smith  3 , Carl H Snyderman  6 , Maie A St John  2 , Phillip B Storm  4 , Jeffrey D Suh  2 , Marilene B Wang  2 , Eric W Wang  6 , Edward C Kuan  1   9
Affiliations
Multicenter Study

Unilateral Versus Bilateral Endoscopic Resection of Olfactory Neuroblastoma: Pooled Analysis From Prospective and Retrospective Multicenter Data

Arash Abiri et al. Int Forum Allergy Rhinol. 2025 Jun.

Abstract

Background: Olfactory neuroblastoma (ONB) is a rare sinonasal malignancy primarily treated with surgery. For tumors arising from the olfactory area, traditional treatment involves transcribriform resection of the anterior cranial fossa. Surgery can be performed with unilateral or bilateral resection depending on extent of involvement; however, there are currently no studies comparing outcomes between the two.

Methods: Prospective and retrospective data on primary ONB patients were collected from a multicenter registry involving eight academic sites. Propensity score matching (PSM) was used to create patient cohorts with similar baseline characteristics. Cox proportional hazards and Kaplan Meier analyses assessed overall survival (OS). Logistic regression assessed associations between extent of resection (unilateral versus bilateral) and tumor recurrence or postoperative cerebrospinal fluid (CSF) leak.

Results: A total of 187 ONB patients (47.6% female) with an average age of 53.6 ± 15.1 years were analyzed. Most tumors were unilateral (81.3%) and predominantly Kadish C (58.3%) or Hyams II (55.8%). Overall, 56.7% of patients underwent bilateral resection. Fifty-four patients experienced tumor recurrence and nine had postoperative CSF leaks. Following PSM (n = 45/group), extent of resection was not associated with mortality (hazard ratio [HR] 1.73; p = 0.407) or OS (p = 0.400). There was no association between extent of resection and recurrence (odds ratio [OR] 0.90; p = 0.814) or postoperative CSF leak (OR 1.54; p = 0.647).

Conclusions: For ONB tumors where unilateral resection may be feasible and oncologically sound, the decision for unilateral versus bilateral resection showed no significant effect on survival, recurrence, or postoperative CSF leak. Oncologic outcomes may be comparable when resection is tailored to individual patient and tumor characteristics.

Keywords: endoscopic surgery; esthesioneuroblastoma; olfactory neuroblastoma; outcomes; resection; survival.

PubMed Disclaimer

Conflict of interest statement

N.D.A. served as consultant for Acclarent, Optinose, and 3‐D Matrix. In the last 36 months, D.M.B. has received grant support from NIH/NHLBI, CF Foundation, International Society of Inflammation and Allergy of the Nose, and the American Rhinologic Society CORE/Sue Ann and John L. Weinberg Foundation; honoraria from sources including from National Jewish Health; and consulting fees from Amgen on medicolegal cases and from Garner Health (equity). G.W.C. served as consultant for Tissium, LLC, and Medtronic ENT. E.H.C. served as consultant for Sanofi/Regeneron and received grant funding from NIH. P.H.H. served as consultant for Stryker and Medtronic, and consultant/equity for Slate Therapeutics. He also holds equity in SoundHealth. J.V.N. served as consultant for Aerin Medical and also holds equity/patent with SpirAir LLC. He has also received grant support from the National Institutes of Health (NIH). Z.M.P. served as consultant/advisor for Medtronic, Optinose, Regeneron/Sanofi, Ethicon J&J, Mediflix, Consumer Medical, and SoundHealth. She also holds equity in Olfera Therapeutics, CORE/Sue Ann, and John L. Weinberg Foundation. She received honoraria and consulting fees from Amgen, on medicolegal cases, and Garner Health (equity). C.H.S. served as consultant for SPIWay and LLC, and holds equity in Respair, Inc. E.C.K. served as consultant for Stryker and 3‐D Matrix, and received royalties from Springer. E.W.W. received grant support from NIH/NIAID. All other authors have no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Kaplan–Meier survival curves of (A) all patients with olfactory neuroblastoma and those stratified by (B) Hyams grade, (C) Kadish stage, and (D) treatment regimen. aRT = adjuvant radiotherapy.
FIGURE 2
FIGURE 2
Kaplan–Meier survival curves of propensity‐score matched patients (N = 90) with olfactory neuroblastoma who (A) underwent unilateral versus bilateral endoscopic tumor resection or (B) experienced tumor recurrence.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Limaiem F. and Das J. M., “Esthesioneuroblastoma,” in StatPearls (Treasure Island (FL): StatPearls Publishing, 2024), http://www.ncbi.nlm.nih.gov/books/NBK539694/.
    1. Su S. Y., Bell D., and Hanna E. Y., “Esthesioneuroblastoma, Neuroendocrine Carcinoma, and Sinonasal Undifferentiated Carcinoma: Differentiation in Diagnosis and Treatment,” International Archives of Otorhinolaryngology 18, no. 2 (2014): S149–S156, 10.1055/s-0034-1390014. - DOI - PMC - PubMed
    1. Goshtasbi K., Abiri A., Abouzari M., et al., “Hyams Grading as a Predictor of Metastasis and Overall Survival in Esthesioneuroblastoma: A Meta‐Analysis,” International Forum of Allergy & Rhinology 9, no. 9 (2019): 1054, 10.1002/alr.22373. - DOI - PMC - PubMed
    1. Carey R. M., Godovchik J., Workman A. D., et al., “Patient, Disease, and Treatment Factors Associated With Overall Survival in Esthesioneuroblastoma,” International Forum of Allergy & Rhinology 7, no. 12 (2017): 1186–1194, 10.1002/alr.22027. - DOI - PubMed
    1. Kuan E. C., Nasser H. B., Carey R. M., et al., “A Population‐Based Analysis of Nodal Metastases in Esthesioneuroblastomas of the Sinonasal Tract,” Laryngoscope 129, no. 5 (2019): 1025–1029, 10.1002/lary.27301. - DOI - PubMed

Publication types